- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2022-08-30
2027-12-01
2028-12-01
200
NCT05428358
University of Aarhus
University of Aarhus
INTERVENTIONAL
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2022-06-16 | N/A | 2025-03-26 |
2022-06-16 | N/A | 2025-03-27 |
2022-06-23 | N/A | 2025-03 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
Diagnostic
Allocation:
Na
Interventional Model:
Single Group
Masking:
None
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| EXPERIMENTAL: Preoperative MRI MRI before surgery. | DIAGNOSTIC_TEST: Preoperative MRI
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Change in treatment strategy | Change in treatment strategy from intended curative resection to other treatment based on MRI scan | 1 week |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Liver metastases | Proportion of patients who had liver metastases detected on MRI | 1 week |
| Surgery | Proportion of patients who made it to surgery/exploration | 1 month |
| Resection | Proportion of patients in each arm who had a pancreatic resection performed | 1 month |
| Intraoperatively detected liver metastases | Proportion of patients with intraoperatively detected liver metastases not seen on either CT or MRI. | 1 month |
| Overall survival (1-year) | 1-year overall survival. | 1 year |
| Overall survival (3-year) | 3-year overall survival. | 3 years |
| Recurrence-free survival | Recurrence-free survival according to final treatment strategy. | 3 years |
| Healthcare costs | Healthcare costs in patients with change of treatment. | 3 years |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Jakob Kirkegård, MD, PhD Phone Number: +4522900604 Email: jakob.kirkegaard@auh.rm.dk |
Study Contact Backup Name: Frank Mortensen, MD, DMSc Phone Number: +45222517296 Email: frmort@rm.dk |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
